Paul Carey

I have been enrolled in the double-blind trial of Tyvaso for IPF since early January.

The medication (or placebo, as the case may be) is received via a nebulizer that delivers a programmed number of metered doses, four times a day. The titration process begins with inhalation of 3 measured doses (4x daily), then ramps up an additional dose each…[Read more]

IPF is typically difficult to diagnose; in my case the onset of symptoms was experienced in 2015, with the actual diagnosis in June 2018 following a lung biopsy.  Referral to an experienced Pulmonologist is essential – the earlier, the better.  Describing the progression as “mild to moderate to severe” I am currently in what is characterized as t…[Read more]